RIGL – Rigel Pharmaceuticals Inc.

RIGL — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

20.85

Margin Of Safety %

Put/Call OI Ratio

0.31

EPS Next Q Diff

-0.07

EPS Last/This Y

-15.6

EPS This/Next Y

Price

30.51

Target Price

51.2

Analyst Recom

1.8

Performance Q

-35.13

Upside

705.7%

Beta

1.28

Ticker: RIGL

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-11	RIGL	27.23	0.35	0.29	5192
2026-03-12	RIGL	26.57	0.34	0.15	5166
2026-03-13	RIGL	26.6	0.34	0.35	5166
2026-03-17	RIGL	26.36	0.37	0.39	5221
2026-03-18	RIGL	25.42	0.37	0.96	5239
2026-03-19	RIGL	25.96	0.32	1.06	5078
2026-03-20	RIGL	25.98	0.30	0.20	5012
2026-03-23	RIGL	26.46	0.39	0.05	2396
2026-03-24	RIGL	26.12	0.37	0.37	2516
2026-03-25	RIGL	26.29	0.37	0.37	2569
2026-03-26	RIGL	26.35	0.36	0.22	2614
2026-03-27	RIGL	25.82	0.36	1.56	2617
2026-03-30	RIGL	25.75	0.36	0.08	2614
2026-03-31	RIGL	27.06	0.36	0.02	2627
2026-04-01	RIGL	27.54	0.35	0.08	2692
2026-04-02	RIGL	27.56	0.34	0.05	2720
2026-04-06	RIGL	27.41	0.34	0.03	2745
2026-04-07	RIGL	28.73	0.32	0.61	2836
2026-04-08	RIGL	29.78	0.35	0.04	2951
2026-04-09	RIGL	30.55	0.31	0.39	3290
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-11	RIGL	27.23	38.4	-34.3	4.80
2026-03-12	RIGL	26.59	38.4	-32.3	4.80
2026-03-13	RIGL	25.95	38.4	-32.2	4.80
2026-03-17	RIGL	26.34	38.4	-30.3	4.80
2026-03-18	RIGL	25.43	38.4	-33.8	4.80
2026-03-19	RIGL	26.02	38.4	-26.3	4.80
2026-03-20	RIGL	25.96	38.4	-29.9	4.80
2026-03-23	RIGL	26.47	38.4	-27.1	4.80
2026-03-24	RIGL	26.11	38.4	-31.2	4.80
2026-03-25	RIGL	26.26	38.4	-28.6	4.80
2026-03-26	RIGL	26.37	38.4	-29.0	4.80
2026-03-27	RIGL	25.82	38.4	-31.9	4.80
2026-03-30	RIGL	25.71	38.4	-29.8	4.80
2026-03-31	RIGL	27.02	38.4	-23.0	4.80
2026-04-01	RIGL	27.51	38.4	-27.1	4.80
2026-04-02	RIGL	27.54	38.4	-29.3	4.80
2026-04-06	RIGL	27.37	38.4	-30.1	4.80
2026-04-07	RIGL	28.71	38.4	-23.3	4.80
2026-04-08	RIGL	29.73	38.4	-25.1	4.80
2026-04-09	RIGL	30.51	38.4	-26.3	4.80
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-11	RIGL	-0.68	6.55	20.98
2026-03-12	RIGL	-0.68	6.55	20.98
2026-03-13	RIGL	-0.68	6.55	20.98
2026-03-17	RIGL	-0.68	6.55	20.98
2026-03-18	RIGL	-0.68	6.55	20.98
2026-03-19	RIGL	-0.68	6.55	20.98
2026-03-20	RIGL	-0.68	6.55	20.98
2026-03-23	RIGL	-0.68	6.49	20.98
2026-03-24	RIGL	-0.68	6.49	20.98
2026-03-25	RIGL	-0.68	6.49	20.85
2026-03-26	RIGL	-0.68	6.49	20.85
2026-03-27	RIGL	-0.68	6.49	20.85
2026-03-30	RIGL	-0.68	6.51	20.85
2026-03-31	RIGL	-0.68	6.51	20.85
2026-04-01	RIGL	-0.68	6.51	20.85
2026-04-02	RIGL	-0.68	6.51	20.85
2026-04-06	RIGL	-0.68	6.52	20.85
2026-04-07	RIGL	-0.68	6.52	20.85
2026-04-08	RIGL	-0.68	6.52	20.85
2026-04-09	RIGL	-0.68	6.52	20.85
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

1.14

Avg. EPS Est. Current Quarter

0.87

Avg. EPS Est. Next Quarter

1.06

Insider Transactions

-0.68

Institutional Transactions

6.52

Beta

1.28

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

38.08

Quality Score

100

Growth Score

Sentiment Score

Actual DrawDown %

41.6

Max Drawdown 5-Year %

-85.2

Target Price

51.2

P/E

1.61

Forward P/E

7.32

PEG

P/S

1.92

P/B

1.43

P/Free Cash Flow

7.45

EPS

18.91

Average EPS Est. Cur. Y

4.8

EPS Next Y. (Est.)

4.8

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

124.72

Relative Volume

1.04

Return on Equity vs Sector %

66.4

Return on Equity vs Industry %

82.8

EPS 1 7Days Diff

0.8

EPS 1 30Days Diff

0.92

EBIT Estimation

-26.3

◆ RIGL Healthcare

$30.51

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

2/20

Pullback

6/25

Volume

4/15

Valuation

18/20

TP/AR

3/10

Options

7/10

RSI

60.9

Range 1M

97.2%

Sup Dist

5.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

11/30

Estimates

7/20

Inst/Vol

7/15

Options

10/10

EPS Yr

-77.7%

EPS NY

-4.1%

52W%

40.4%

💎

Long-Term Value

Quality companies, undervalued

WATCH

🟢 BUY +73.3% upside

Quality

29/30

Valuation

20/30

Growth

7/25

Stability

9/10

LT Trend

0/5

Upside

+73.3%

Quality

100

MoS

25%

Rigel Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 172

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

RIGL

Latest News

—

Caricamento notizie per RIGL…

stock quote shares RIGL – Rigel Pharmaceuticals Inc. Stock Price stock today

news today RIGL – Rigel Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RIGL – Rigel Pharmaceuticals Inc. yahoo finance google finance

stock history RIGL – Rigel Pharmaceuticals Inc. invest stock market

stock prices RIGL premarket after hours

ticker RIGL fair value insiders trading

RIGL – Rigel Pharmaceuticals, Inc.

RIGL — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

20.85

Margin Of Safety %

Put/Call OI Ratio

0.31

EPS Next Q Diff

-0.07

EPS Last/This Y

-15.6

EPS This/Next Y

Price

30.51

Target Price

51.2

Analyst Recom

1.8

Performance Q

-35.13

Upside

705.7%

Beta

1.28

Ticker: RIGL

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-11	RIGL	27.23	0.35	0.29	5192
2026-03-12	RIGL	26.57	0.34	0.15	5166
2026-03-13	RIGL	26.6	0.34	0.35	5166
2026-03-17	RIGL	26.36	0.37	0.39	5221
2026-03-18	RIGL	25.42	0.37	0.96	5239
2026-03-19	RIGL	25.96	0.32	1.06	5078
2026-03-20	RIGL	25.98	0.30	0.20	5012
2026-03-23	RIGL	26.46	0.39	0.05	2396
2026-03-24	RIGL	26.12	0.37	0.37	2516
2026-03-25	RIGL	26.29	0.37	0.37	2569
2026-03-26	RIGL	26.35	0.36	0.22	2614
2026-03-27	RIGL	25.82	0.36	1.56	2617
2026-03-30	RIGL	25.75	0.36	0.08	2614
2026-03-31	RIGL	27.06	0.36	0.02	2627
2026-04-01	RIGL	27.54	0.35	0.08	2692
2026-04-02	RIGL	27.56	0.34	0.05	2720
2026-04-06	RIGL	27.41	0.34	0.03	2745
2026-04-07	RIGL	28.73	0.32	0.61	2836
2026-04-08	RIGL	29.78	0.35	0.04	2951
2026-04-09	RIGL	30.55	0.31	0.39	3290
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-11	RIGL	27.23	38.4	-34.3	4.80
2026-03-12	RIGL	26.59	38.4	-32.3	4.80
2026-03-13	RIGL	25.95	38.4	-32.2	4.80
2026-03-17	RIGL	26.34	38.4	-30.3	4.80
2026-03-18	RIGL	25.43	38.4	-33.8	4.80
2026-03-19	RIGL	26.02	38.4	-26.3	4.80
2026-03-20	RIGL	25.96	38.4	-29.9	4.80
2026-03-23	RIGL	26.47	38.4	-27.1	4.80
2026-03-24	RIGL	26.11	38.4	-31.2	4.80
2026-03-25	RIGL	26.26	38.4	-28.6	4.80
2026-03-26	RIGL	26.37	38.4	-29.0	4.80
2026-03-27	RIGL	25.82	38.4	-31.9	4.80
2026-03-30	RIGL	25.71	38.4	-29.8	4.80
2026-03-31	RIGL	27.02	38.4	-23.0	4.80
2026-04-01	RIGL	27.51	38.4	-27.1	4.80
2026-04-02	RIGL	27.54	38.4	-29.3	4.80
2026-04-06	RIGL	27.37	38.4	-30.1	4.80
2026-04-07	RIGL	28.71	38.4	-23.3	4.80
2026-04-08	RIGL	29.73	38.4	-25.1	4.80
2026-04-09	RIGL	30.51	38.4	-26.3	4.80
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-11	RIGL	-0.68	6.55	20.98
2026-03-12	RIGL	-0.68	6.55	20.98
2026-03-13	RIGL	-0.68	6.55	20.98
2026-03-17	RIGL	-0.68	6.55	20.98
2026-03-18	RIGL	-0.68	6.55	20.98
2026-03-19	RIGL	-0.68	6.55	20.98
2026-03-20	RIGL	-0.68	6.55	20.98
2026-03-23	RIGL	-0.68	6.49	20.98
2026-03-24	RIGL	-0.68	6.49	20.98
2026-03-25	RIGL	-0.68	6.49	20.85
2026-03-26	RIGL	-0.68	6.49	20.85
2026-03-27	RIGL	-0.68	6.49	20.85
2026-03-30	RIGL	-0.68	6.51	20.85
2026-03-31	RIGL	-0.68	6.51	20.85
2026-04-01	RIGL	-0.68	6.51	20.85
2026-04-02	RIGL	-0.68	6.51	20.85
2026-04-06	RIGL	-0.68	6.52	20.85
2026-04-07	RIGL	-0.68	6.52	20.85
2026-04-08	RIGL	-0.68	6.52	20.85
2026-04-09	RIGL	-0.68	6.52	20.85
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

1.14

Avg. EPS Est. Current Quarter

0.87

Avg. EPS Est. Next Quarter

1.06

Insider Transactions

-0.68

Institutional Transactions

6.52

Beta

1.28

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

38.08

Quality Score

100

Growth Score

Sentiment Score

Actual DrawDown %

41.6

Max Drawdown 5-Year %

-85.2

Target Price

51.2

P/E

1.61

Forward P/E

7.32

PEG

P/S

1.92

P/B

1.43

P/Free Cash Flow

7.45

EPS

18.91

Average EPS Est. Cur. Y

4.8

EPS Next Y. (Est.)

4.8

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

124.72

Relative Volume

1.04

Return on Equity vs Sector %

66.4

Return on Equity vs Industry %

82.8

EPS 1 7Days Diff

0.8

EPS 1 30Days Diff

0.92

EBIT Estimation

-26.3

◆ RIGL Healthcare

$30.51

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

2/20

Pullback

6/25

Volume

4/15

Valuation

18/20

TP/AR

3/10

Options

7/10

RSI

60.9

Range 1M

97.2%

Sup Dist

5.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

11/30

Estimates

7/20

Inst/Vol

7/15

Options

10/10

EPS Yr

-77.7%

EPS NY

-4.1%

52W%

40.4%

💎

Long-Term Value

Quality companies, undervalued

WATCH

🟢 BUY +73.3% upside

Quality

29/30

Valuation

20/30

Growth

7/25

Stability

9/10

LT Trend

0/5

Upside

+73.3%

Quality

100

MoS

25%

Rigel Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 172

RIGL

Latest News

—

Caricamento notizie per RIGL…

stock quote shares RIGL – Rigel Pharmaceuticals, Inc. Stock Price stock today

news today RIGL – Rigel Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RIGL – Rigel Pharmaceuticals, Inc. yahoo finance google finance

stock history RIGL – Rigel Pharmaceuticals, Inc. invest stock market

stock prices RIGL premarket after hours

ticker RIGL fair value insiders trading

RIGL – Rigel Pharmaceuticals Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: RIGL

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

RIGL – Rigel Pharmaceuticals, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: RIGL

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y